25.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer (PFE) Faces Legal Challenges Over Depo-Provera's Increased Brain Tumor Risk - simplywall.st
Pfizer’s New Phase 1 Study: A Potential Game-Changer? - TipRanks
Pfizer’s Pediatric Pantoprazole Study: A Market Watch - TipRanks
Pfizer Bolsters Oncology Pipeline with $1.25B 3SBio Deal - Contract Pharma
Pfizer faces lawsuits over Depo-Provera cancer risk (PFE:NYSE) - Seeking Alpha
Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits - GlobeNewswire
Pfizer licenses cancer immunotherapy from 3SBio in $1.25 billion deal - Investing.com
Pfizer Completes Licensing Agreement with 3SBio - Business Wire
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings - The Globe and Mail
Ex-Dividend Reminder: GE HealthCare Technologies, Pfizer and Old Second Bancorp - Nasdaq
Pfizer Nears Major Bottom: A Turning Point for Investors? - FXEmpire
Pfizer: Building The Next Oncology Empire - Seeking Alpha
Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income - Yahoo Finance
Here's What To Expect From Pfizer's Non-Oncology Drugs In Q2 Earnings - Barchart.com
Pfizer Stock (PFE) Opinions on Stagnant Performance and Policy Risks - Quiver Quantitative
Is Pfizer Inc. a good long term investmentRecord-setting profit potential - Autocar Professional
What analysts say about Pfizer Inc. stockBreakthrough profits - jammulinksnews.com
Pfizer Inc. (NYSE:PFE) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed? - Yahoo Finance
Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II - insights.citeline.com
Request for Proposals: Pfizer Independent Medical Education Grant Program - fundsforNGOs
Lobbying Update: $3,490,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - AOL.com
What drives Pfizer Inc. stock priceFree Stock Market Return Analysis - Jammu Links News
Pfizer Inc. Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Can Pfizer Limited (PFIZER) Maintain Its ValuationFree Market Volatility Navigation Tips - Jammu Links News
Pfizer’s Discounted Stock Offers Yield, But Risks Linger - Finimize
Sally Susman helped steer Pfizer through COVID-19. Her advice for leaders? Learn to write — and listen. - Business Insider
Pfizer Inc. - Britannica
Pfizer’s (PFE) Dividend Safety: Balancing Innovation and Shareholder Returns - Yahoo Finance
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Morgan Stanley Maintains a Hold on Pfizer (PFE) - MSN
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - MSN
Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes - TipRanks
Pfizer’s BeneFIX Study Update: Key Insights for Investors - TipRanks
Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer in Maternal Health - TipRanks
Pfizer’s Lyme Disease Vaccine Study: Key Insights for Investors - TipRanks
Pfizer’s Rimegepant Study: A New Hope for Migraine Sufferers - TipRanks
Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention? - TipRanks
Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer in Infant RSV Prevention - TipRanks
Pfizer's Global Health Fellows Program: Leveraging Colleagues’ Expertise to Help Improve Healthcare Access Around the World - Pfizer
Pfizer’s Latest Study on PF-07799544: A Potential Game-Changer for Advanced Solid Tumors - TipRanks
Rx Rundown: Sarepta Therapeutics, Juul, Pfizer and more - Medical Marketing and Media
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Pfizer, Lilly spend big on telehealth contracts: Lawmaker report - Sherwood News
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit - insights.citeline.com
Pfizer Just Reversed Its Bull Run. Is It A Buy Or A Sell? - Investor's Business Daily
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):